150 S Saunder Road
About Horizon Pharma
At Horizon Pharma, we are focused on improving patients' lives by developing, acquiring, commercializing and delivering breakthrough medicines to patients because we understand the challenges they face. We market 11 medicines that address unmet treatment needs for rare and rheumatic diseases. By leading research for medicines in development, exploring all potential uses for medicines and ensuring access to medicines prescribed, we can make a powerful difference for our patients, their caregivers and physicians. The outcomes we attain – and the lengths we go to achieve them – reflect our company ideals, a commitment to our patients and the communities we serve. For us, it's personal: by living up to our own potential, we are helping others live up to theirs.
Stock symbol: HZNP
At Horizon, we work to define ourselves by a different set of numbers - the number of patients helped, lives changed, lives saved. In this video, hear from our employees on why working at Horizon Pharma is personal.
341 articles with Horizon Pharma
Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
Horizon Pharma plc announced that it has won a PR News CSR Award in the Corporation category for its impactful partnership with Chicago-based charter school, Perspectives Math and Science Academy.
Offering proceeds, along with balance sheet cash, expected to fund a debt reduction of ~$550 million
Horizon Pharma plc announced that the compensation committee of its board of directors approved the grant on March 1, 2018 of inducement restricted stock units for an aggregate of 8,544 ordinary shares to six new employees.
Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints
Horizon Pharma plc announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease
Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance
Horizon Pharma plc announced its fourth-quarter and full-year 2018 financial results and provided its full-year 2019 net sales and adjusted EBITDA guidance.
The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com.
Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019
Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout.
Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
Horizon Pharma plc today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with a urea cycle disorder (UCD).
Timothy P. Walbert, chairman, president and chief executive officer, will present at 4:30 p.m. PT on Jan. 8, 2019.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Horizon Pharma plc (Nasdaq: HZNP) announced today that the company will participate in the following conferences
Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
Quarterly Net Sales Increased 20 Percent to $325.3 Million, a Record for the Company; Third-Quarter 2018 GAAP Net Income of $26.0 Million; Adjusted EBITDA of $149.9 Million
Horizon Pharma plc (Nasdaq: HZNP) has been awarded a 2018 Top Workplaces honor by the Chicago Tribune.
Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
Horizon Pharma plc announced that more detailed results from the 48 week off-therapy follow-up to the Phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the American Academy of Ophthalmology (AAO) Annual Meeting, Oct. 27 – 30, 2018, in Chicago, Ill.
A replay of the webcast will be available for each event.
Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
Horizon Pharma plc (Nasdaq: HZNP) today announced multiple presentations showing that people who have undergone a kidney transplant experience higher rates of uncontrolled gout compared to other renal disease patients, and mortality rates were higher in kidney transplant recipients diagnosed with gout.
Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
Horizon to also host onsite discussion with prominent researchers on pathophysiology of gout
FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
The Best Small & Medium Workplaces list is one of a series of rankings by Great Place to Work and FORTUNE based on employee feedback from Great Place to Work-Certified™ organizations.
Horizon Pharma (Nasdaq: HZNP) announced today that its third-quarter financial results will be released on Wednesday, Nov. 7, 2018.